AHA Key Events

Print This Page

Tell a Colleague

Prescribing Information

About ANGIOMAX

Clinical Information

About PCI

Bleeding – a Predictor
of Mortality

About HIT/HITTS

Removal of the Femoral
Arterial Catheter

Medical Information

Helpful Resources

ANGIOMAX Key Events at:

Mode of Action Video

See a vivid demonstration of ANGIOMAX in action. Watch ANGIOMAX: Thrombin-Specific Inhibition for Preventing Thrombosis and Thrombin-Mediated Platelet Activation.

Key Events at AHA 2007

Monday, November 5, 2007

Oral Abstract Presentations

3:00 PM Room W240 Abstract #2217	“Impact of the ACUITY and TIMI Major Bleeding Definitions on One-Year Mortality in Patients with Acute Coronary Syndromes” (Manoukian, et al)
4:45 PM Room W240 Abstract #2222	“Long-term Outcomes of Acute Coronary Syndrome Patients with Chronic Renal Insufficiency treated with Bivalirudin vs Heparin plus a Glycoprotein IIb/IIIa Inhibitor: One Year Results from the Randomized ACUITY Trial” (Mehran, et al)

Wednesday, November 7, 2007
Poster Sessions 9:30–11:00 AM in West Hall A1-A2
Abstract #3204/C5	“Implications of Preoperative Thienopyridine Use in Patients With non-ST Elevation Acute Coronary Syndrome Undergoing Coronary Artery Bypass Surgery: One year Results From the ACUITY Trial” (Ebrahimi, et al)
Abstract #3220/C21	“Bivalirudin Monotherapy Provides Similar One-Year Survival Compared to Heparin plus GP IIb/IIIa Inhibitors in Diabetic Patients with Acute Coronary Syndromes: Results from the Randomized ACUITY Trial” (Feit, et al)

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (

10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.